Calcium’s relationship with cancer risk is genuinely two-sided, and that nuance rarely comes through in headlines. The same mineral that appears protective against colorectal cancer shows a modest, still-debated association with increased prostate cancer risk — meaning there’s no single, simple answer to whether more calcium is “good” or “bad” when it comes to cancer. Here’s what the actual research shows for each.
Calcium Appears to Lower Colorectal Cancer Risk
The evidence connecting calcium to colorectal cancer leans meaningfully in a protective direction. A large prospective analysis using UK Biobank data, following more than 114,000 participants over a median of 9.4 years, found that higher dietary calcium intake was associated with a 29% lower risk of colorectal cancer when comparing the highest to lowest intake groups. This protective association held for total dairy protein and protein from milk as well, suggesting the effect isn’t limited to calcium consumed in isolation.
Clinical trial evidence backs this up further. A randomized trial of patients with a history of colorectal adenomas (precancerous growths) found that calcium carbonate supplementation was associated with reduced adenoma recurrence compared to placebo. A separate randomized pilot study of 220 patients with previously resected colorectal cancer found a statistically significant reduction in the odds of cancer recurrence among those given calcium carbonate supplements compared to placebo.
There’s also a global public health angle here: research using Global Burden of Disease data found that low dietary calcium intake contributes to a disproportionately higher colorectal cancer burden specifically in countries with lower social development, suggesting that inadequate calcium intake at a population level may be a meaningful, addressable contributor to colorectal cancer disparities worldwide.
Calcium Shows a Modest, Contested Link to Prostate Cancer Risk
The picture flips somewhat for prostate cancer, though the evidence here is considerably less consistent. A 2025 systematic review and meta-analysis of 21 prospective cohort studies found that high intakes of total, dietary, and dairy calcium were each associated with modestly increased prostate cancer risk — with dairy calcium showing the strongest association among the three. The researchers were explicit that this relationship remains weak and its dose-response pattern unclear, rather than a firmly established causal link.
Other research adds important caveats to this association. A prospective study using the Health Professionals Follow-up Study, tracking nearly 48,000 men, noted that while several studies have found positive associations between calcium and prostate cancer risk, other studies find no association or only weak support for one. Notably, a secondary analysis of a randomized clinical trial testing calcium supplementation found no increased prostate cancer risk, and if anything, a suggestive lower risk among men given 1,200 mg of calcium daily — a finding that runs directly counter to the observational studies showing increased risk, and highlights genuine inconsistency in the evidence base.
Importantly, Mendelian randomization studies — which use genetic evidence to test whether an association reflects actual causation — have not supported a causal role for calcium in prostate cancer, further suggesting the observed association in some studies may reflect other factors rather than calcium itself directly driving cancer development.
Why Dairy Specifically Might Matter More Than Calcium Alone
One consistent thread across the prostate cancer research is that dairy-sourced calcium shows a stronger association with risk than non-dairy calcium sources. Researchers suspect this may reflect other compounds present in dairy beyond calcium itself — including IGF-1, natural estrogens, and saturated fat — rather than calcium being the primary driver. High dairy intake may also lower vitamin D levels due to dairy’s phosphorus content, adding another potential confounding factor that makes isolating calcium’s specific role genuinely difficult.
The Practical Takeaway
Given the mixed and sometimes contradictory evidence, a few reasonable conclusions emerge. The colorectal cancer protective association is more consistent and appears in both observational and randomized trial data, making it the stronger and more reliable finding of the two. The prostate cancer association is weaker, inconsistent across study types, and not supported by genetic causal analysis — meaning it shouldn’t be treated as a settled concern requiring dramatic dietary changes. For men specifically concerned about prostate cancer risk, sourcing calcium from non-dairy foods rather than heavily restricting calcium altogether is a reasonable middle-ground approach discussed in some of the research, though this remains a precautionary suggestion rather than a strongly evidence-backed recommendation.
When to Talk to a Doctor
Calcium needs vary by age, sex, and individual health circumstances, and anyone considering significant changes to calcium intake — particularly high-dose supplementation, or restriction due to cancer risk concerns — should discuss it with a doctor rather than making major changes based on population-level research alone. This is especially true for anyone with a personal or family history of colorectal or prostate cancer, since individual risk factors can meaningfully change how this general research should be applied to a specific person’s situation.
Join The Discussion
Has calcium intake come up in conversations with your own doctor, whether around bone health or cancer risk specifically? Share what guidance you’ve received, or questions you still have about balancing calcium’s different effects across different cancer types. This is a genuinely nuanced area of ongoing research, so if you’re weighing calcium supplementation for a specific health reason, it’s worth bringing this kind of research directly to a doctor who knows your full medical picture.
